Scholarlink

Background <p>This retrospective study aimed to evaluate the efficacy of transepithelial accelerated corneal cross-linking&#xa0;(transEpi ACXL) when applied separately or combined with phototherapeutic keratectomy (transPTK ACXL) in keratoconic eyes using biomechanical parameters.</p> Methods <p>The study included eyes with progressive keratoconus treated with either continuous transEpi ACXL or transPTK ACXL with 6&#xa0;months follow-up. The following parameters were assessed preoperatively and 6&#xa0;months postoperatively: biomechanically corrected intraocular pressure (bIOP), maximum and mean keratometry (K<sub>max</sub> and K<sub>m</sub>), minimum and central corneal thickness (MCT and CCT), corneal coma, best-corrected visual acuity (BCVA), deformation amplitude ratio at 2&#xa0;mm nasal/temporal (DAR2), integrated inverse radius (IIR), stiffness parameter at first applanation (SP-A1), highest concavity time (HCT) and two versions of stress–strain index (SSIv1 and SSIv2).</p> Results <p>A total of 75 eyes from 72 patients were included (31 in the transEpi ACXL group and 44 in the transPTK ACXL group). The two groups were comparable in age (23.0 ± 5.0 vs. 21.3 ± 5.2&#xa0;years) and TKC grade distribution (grades 1–4), with no statistically significant between-group differences (<i>P</i> = 0.321 and 0.766, respectively). Both groups exhibited significant reductions in IIR, and increases in SSIv1 and SSIv2 (all <i>P</i> &lt; 0.05). The improvements in K<sub>max</sub>, coma, and SSIv2 were greater in the transPTK ACXL group than in the transEpi ACXL group (all <i>P</i> &lt; 0.05). The relative difference in SSIv2 (SSIv2<sub>Rdif</sub>) exceeded those of other biomechanical parameters in both groups (transEpi ACXL: SSIv2<sub>Rdif</sub> &gt; DAR2<sub>Rdif</sub>, IIR<sub>dif</sub>; transPTK ACXL: SSIv2<sub>Rdif</sub> &gt; DAR2<sub>Rdif</sub>, IIR<sub>Rdif</sub>, SP-A1<sub>Rdif</sub>, HCT<sub>Rdif</sub>, and SSIv1<sub>Rdif</sub>, all <i>P</i> &lt; 0.05).</p> Conclusions <p>TransPTK ACXL resulted in better biomechanical and visual benefits in comparison with transEpi ACXL 6&#xa0;months after treatment. SSIv2 demonstrated superior performance in assessing the efficacy of corneal cross-linking.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Variation in corneal biomechanical properties following continuous cross-linking treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • ChenHao Zhao,
  • XinYu Yao,
  • YeWei Zhao,
  • HongJiang Wu,
  • JiaHui Zong,
  • XuanYa Tong,
  • Daniela Oehring,
  • Lan Yang,
  • XiaoFei Zhou,
  • Ying Li,
  • YanJie Shen,
  • YuFeng Ye,
  • ShiHao Chen,
  • Jia Qu,
  • QinMei Wang,
  • Ahmed Elsheikh,
  • FangJun Bao

摘要

Background

This retrospective study aimed to evaluate the efficacy of transepithelial accelerated corneal cross-linking (transEpi ACXL) when applied separately or combined with phototherapeutic keratectomy (transPTK ACXL) in keratoconic eyes using biomechanical parameters.

Methods

The study included eyes with progressive keratoconus treated with either continuous transEpi ACXL or transPTK ACXL with 6 months follow-up. The following parameters were assessed preoperatively and 6 months postoperatively: biomechanically corrected intraocular pressure (bIOP), maximum and mean keratometry (Kmax and Km), minimum and central corneal thickness (MCT and CCT), corneal coma, best-corrected visual acuity (BCVA), deformation amplitude ratio at 2 mm nasal/temporal (DAR2), integrated inverse radius (IIR), stiffness parameter at first applanation (SP-A1), highest concavity time (HCT) and two versions of stress–strain index (SSIv1 and SSIv2).

Results

A total of 75 eyes from 72 patients were included (31 in the transEpi ACXL group and 44 in the transPTK ACXL group). The two groups were comparable in age (23.0 ± 5.0 vs. 21.3 ± 5.2 years) and TKC grade distribution (grades 1–4), with no statistically significant between-group differences (P = 0.321 and 0.766, respectively). Both groups exhibited significant reductions in IIR, and increases in SSIv1 and SSIv2 (all P < 0.05). The improvements in Kmax, coma, and SSIv2 were greater in the transPTK ACXL group than in the transEpi ACXL group (all P < 0.05). The relative difference in SSIv2 (SSIv2Rdif) exceeded those of other biomechanical parameters in both groups (transEpi ACXL: SSIv2Rdif > DAR2Rdif, IIRdif; transPTK ACXL: SSIv2Rdif > DAR2Rdif, IIRRdif, SP-A1Rdif, HCTRdif, and SSIv1Rdif, all P < 0.05).

Conclusions

TransPTK ACXL resulted in better biomechanical and visual benefits in comparison with transEpi ACXL 6 months after treatment. SSIv2 demonstrated superior performance in assessing the efficacy of corneal cross-linking.